A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Completed · Phase 1 · Has a placebo group

Conditions studied: Acne Vulgaris

In brief

A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study

Key facts

Study ID

NCT02581072

Run by

Novan, Inc.

People needed

56

Starts

2015-10-01

Expected to finish

2016-04-01

Last updated by the study team

2018-11-19

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe acne
• 20 inflammatory and 25 non-inflammatory acne lesions

You may not qualify if…

• Pregnant, trying to become pregnant, or nursing
• Known allergy to any component of the topical SB204 formulation

Where it is running

• Spaulding Clinical Research, LLC — West Bend, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.